{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T23:20:36Z","timestamp":1785799236950,"version":"3.56.0"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T00:00:00Z","timestamp":1656892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81871633, 82170122"],"award-info":[{"award-number":["81871633, 82170122"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010270","name":"Capital Health Research and Development of Special Fund","doi-asserted-by":"publisher","award":["2020-1-2022"],"award-info":[{"award-number":["2020-1-2022"]}],"id":[{"id":"10.13039\/501100010270","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Epstein\u2013Barr virus (EBV)\u2013related hemophagocytic lymphohistiocytosis (HLH) is an abnormal inflammation caused by EBV infection, which has high mortality during induction therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>This study is aimed to build a model to predict the risk of death during induction therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The patients with EBV-HLH admitted from January 2015 to December 2018 were retrospectively reviewed. The primary outcome was death during induction therapy. The interval from receiving therapy to death or the end of induction therapy was the observing time. The patients admitted from January 2015 to December 2017 were assigned to the primary group, and the patients admitted from January to December 2018 were assigned to the validation group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We included 234 patients with EBV-HLH, of whom 65 (27.4%) died during induction therapy. The middle observing time was 25 days. On the basis of the primary group, the multivariate Cox analysis demonstrated age &amp;gt;18 years, blood urea nitrogen, procalcitonin &amp;gt;2 \u00b5g\/L, serum CD25, and EBV-DNA in peripheral blood mononuclear cell as the risk factors of death during induction therapy. We developed a nomogram integrating the above factors with high predictive accuracy (c-statistic, 0.86) and stratified all patients into the high-risk and the low-risk groups. On the basis of the validation group, the high-risk patients had a higher risk of death (hazard ratio, 4.93; <jats:italic>P =<\/jats:italic> 0.012). In the subgroup analysis based on patients receiving etoposide-based strategy, the mortality in high-risk and low-risk patients was 43.9 and 3.1 per 100 person-weeks, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>We developed a nomogram for risk stratification of patients with EBV-HLH receiving induction therapy.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2022.876415","type":"journal-article","created":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T04:54:41Z","timestamp":1656910481000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["The Outcome of Induction Therapy for EBV-Related Hemophagocytic Lymphohistiocytosis: A Model for Risk Stratification"],"prefix":"10.3389","volume":"13","author":[{"given":"Tingting","family":"Cui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingshi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1532\/IJH97.07012","article-title":"Nationwide Survey of Hemophagocytic Lymphohistiocytosis in Japan","volume":"86","author":"Ishii","year":"2007","journal-title":"Int J Hematol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-788349","article-title":"Confirmed Efficacy of Etoposide and Dexamethasone in HLH Treatment: Long-Term Results of the Cooperative HLH-2004 Study","volume":"130","author":"Bergsten","year":"2017","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1080\/10245332.2018.1491093","article-title":"Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis in Adults and Adolescents-a Life-Threatening Disease: Analysis of 133 Cases From a Single Center","volume":"23","author":"Lai","year":"2018","journal-title":"Hematology"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15988","article-title":"Requirement for Etoposide in the Initial Treatment of Epstein-Barr Virus-Associated Haemophagocytic Lymphohistiocytosis","volume":"186","author":"Song","year":"2019","journal-title":"Br J Haematol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.12.4706.bloodjournal86124706","article-title":"Soluble Interleukin-2 Receptor: A Useful Prognostic Factor for Patients With Hemophagocytic Lymphohistiocytosis","volume":"86","author":"Imashuku","year":"1995","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","first-page":"20406207211020544","DOI":"10.1177\/20406207211020544","article-title":"Natural-Killer Cell Cytotoxicity as a Diagnostic and Prognostic Marker for Adult Patients With Secondary Hemophagocytic Lymphohistiocytosis: A Prospective Phase II Observational Study","volume":"12","author":"Oh","year":"2021","journal-title":"Ther Adv hematol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2018894618","article-title":"Recommendations for the Management of Hemophagocytic Lymphohistiocytosis in Adults","volume":"133","author":"La Rosee","year":"2019","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61048-X","article-title":"Adult Haemophagocytic Syndrome","volume":"383","author":"Ramos-Casals","year":"2014","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2021.07.009","article-title":"Clinical Features and Prognostic Factors of Children With Chronic Active Epstein-Barr Virus Infection: A Retrospective Analysis of a Single-Center","volume":"238","author":"Chen","year":"2021","journal-title":"J Pediatr"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-019-02612-2","article-title":"Factors Predicting the Recurrence of Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis in Children After Treatment Using the HLH-2004 Protocol","volume":"109","author":"Yanagaisawa","year":"2019","journal-title":"Int J Hematol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21795","article-title":"Clinical Significance of Clonality and Epstein-Barr Virus Infection in Adult Patients With Hemophagocytic Lymphohistiocytosis","volume":"85","author":"Ahn","year":"2010","journal-title":"Am J hematol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24039","article-title":"Treatment Choice of Immunotherapy or Further Chemotherapy for Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis","volume":"59","author":"Shiraishi","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-2993-y","article-title":"Clinical Utility of Soluble Interleukin-2 Receptor in Hemophagocytic Syndromes: A Systematic Scoping Review","volume":"96","author":"Lin","year":"2017","journal-title":"Ann hematol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-021-01073-9","article-title":"T Cell-Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis (HLH) Occurs in Non-Asians and Is Associated With a T Cell Activation State That Is Comparable to Primary HLH","volume":"41","author":"Shamriz","year":"2021","journal-title":"J Clin Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2020.11.027","article-title":"Clinical Application of Epstein-Barr Virus DNA Loads in Epstein-Barr Virus-Associated Diseases: A Cohort Study","volume":"82","author":"Yu","year":"2021","journal-title":"J infect"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-143545","article-title":"How I Treat EBV Lymphoproliferation","volume":"114","author":"Heslop","year":"2009","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2015.11.002","article-title":"Diagnostic Values for the Viral Load in Peripheral Blood Mononuclear Cells of Patients With Chronic Active Epstein-Barr Virus Disease","volume":"22","author":"Ito","year":"2016","journal-title":"J Infect Chemother"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-354142","article-title":"Prospective Measurement of Epstein-Barr Virus-DNA in Plasma and Peripheral Blood Mononuclear Cells of Extranodal NK\/T-Cell Lymphoma, Nasal Type","volume":"118","author":"Suzuki","year":"2011","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3109\/10428190009053537","article-title":"Treatment Strategies for Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis (EBV-HLH)","volume":"39","author":"Imashuku","year":"2000","journal-title":"Leuk Lymphoma"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2014.10.012","article-title":"Acute Kidney Injury in Adults With Hemophagocytic Lymphohistiocytosis","volume":"65","author":"Aulagnon","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-3254-4","article-title":"Malignancy and Chemotherapy Induced Haemophagocytic Lymphohistiocytosis in Children and Adolescents-a Single Centre Experience of 20 Years","volume":"97","author":"Strenger","year":"2018","journal-title":"Ann hematol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1186\/s12879-017-2396-7","article-title":"Accuracy of Serum Procalcitonin for the Diagnosis of Sepsis in Neonates and Children With Systemic Inflammatory Syndrome: A Meta-Analysis","volume":"17","author":"Pontrelli","year":"2017","journal-title":"BMC Infect dis"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1097\/PAI.0000000000000552","article-title":"Diagnostic Value of PCT and CRP for Detecting Serious Bacterial Infections in Patients With Fever of Unknown Origin: A Systematic Review and Meta-Analysis","volume":"25","author":"Hu","year":"2017","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.idc.2019.01.001","article-title":"Chemotherapy and Beyond: Infections in the Era of Old and New Treatments for Hematologic Malignancies","volume":"33","author":"Atkins","year":"2019","journal-title":"Infect Dis Clin North Am"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.876415\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T04:54:44Z","timestamp":1656910484000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.876415\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,4]]},"references-count":24,"alternative-id":["10.3389\/fimmu.2022.876415"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.876415","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,4]]},"article-number":"876415"}}